Skip to main content

TheraGenetics Licenses IP from CAMH to Predict Response to Antidepressants

NEW YORK (GenomeWeb News) – Pharmacogenetic diagnostic developer TheraGenetics said today that it has licensed intellectual property from the Centre for Addiction and Mental Health in Ontario, Canada, related to predicting patient response to antidepressants.
 
TheraGenetics, which is developing a suite of tests to guide the treatment of central nervous system disorders, said that the kits will help determine whether certain patients are susceptible to side-effects from antidepressants.
 
The company did not disclose further details of the IP that it licensed or the specific antidepressants that it plans to target with the tests.
 
Richard Kivel, CEO of TheraGenetics, said in a statement that the IP “further augments our capabilities to innovate pharmacogenetic diagnostics tests in a broad range of disorders, including schizophrenia, depression, bipolar disorder, Alzheimer's disease and ADHD."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.